Organization | Indevus Pharmaceuticals

Indevus Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3

Founded: Lexington MA United States (1988)

Status: Acquired by Endo Pharmaceuticals (2009) → now Bristol-Myers Squibb (2001)

Organization Overview

First Clinical Trial

None

First Marketed Drug

2004

trospium (sanctura)

First NDA Approval

2004

trospium (sanctura)

Last Known Activity

2004

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (1)

trospium (sanctura) (2004 NDA)

Drugs in Phase 3 Trials (8)

Key: Indevus Pharmaceuticals (0) Acquired (8)

inactivated influenza vaccine (11 trials)

mrna-1010 (12 trials)

mrna-1083 (2 trials)

mrna-1273 (Spikevax) (20 trials)

mrna-1345 (10 trials)

mrna-1647 (9 trials)

mrna-4157 (4 trials)

pembrolizumab (keytruda) (5 trials)

Drugs in Phase 2 Trials (19)

Key: Indevus Pharmaceuticals (0) Acquired (19)

fluarix (1 trial)

mrna-1010.6 (1 trial)

serogroup B meningococcal vaccine (Bexsero) (1 trial)

varicella zoster virus glycoprotein e antigen (Shingrix) (1 trial)

Drugs in Phase 1 Trials (23)

Key: Indevus Pharmaceuticals (0) Acquired (23)

core-g28v2 60mer mrna vaccine (1 trial)

durvalumab (imfinzi) (2 trials)

eod-gt8 60mer (2 trials)

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi) (1 trial)

Indications

Approved Indications

Urinary Bladder, Overactive

Overview

Highest Phase: None
# of Trials: 80
# of Trial APIs: 50